Table 2

Comparison of NY-ESO-1 expression in sarcoma tumors as assessed by PCR or IHC.

Histological subtype Case no. NY-ESO-1
PCR a IHC b
Gastrointestinal stromal tumor 1 +++ 3/pos
2 - 0/neg
3 + 2/pos
4 - 0/neg
5 - 0/neg
Synovial sarcoma 1 +++ 2-3/pos
2 +++ 3/pos
Uterine leiomyosarcoma 1 + 1/neg
2 - 1/neg
3 - 0/neg
4 + 2/pos
5 +++ 3/pos
Leiomyosarcoma 1 - 0/neg
2 - 1/neg
3 - 0/neg
4 - 1/neg
5 - 0/neg
6 - 0/neg
7 - 1/neg
Angiosarcoma 1 + 1/neg
2 ++ 2/pos
3 - 1/neg
Malignant fibrous histiocytoma 1 ++ 2/pos
2 - 1/neg
3 - 1/neg
4 - 1/neg
5 - 0/neg
Liposarcoma 1 - 1/neg
2 +++ 3/pos
3 - 0/neg
4 - 0/neg
5 - 0/neg
6 - nd
Osteosarcoma 1 - 0/neg
Chondrosarcoma 1 + 0/neg
2 + 1/neg

aNY-ESO-1 expression at the RNA level was assessed by semiquantitative RT-PCR. bNY-ESO-1 expression at the protein level was assessed by IHC using monoclonal antibody ES121 to NY-ESO-1. Scoring: 0, no positive cells; 1, rare and scattered positive cells; 2, < or = 50% positive cells; 3, >50% positive cells; nd, not done. Interpretation: pos, positive; neg, negative.